Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma(CITADEL-310) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT04361851 | Study of Dara-Pembro for Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 26, 2022 |
| clinicaltrials |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT04660045 | Early Intervention With Acalabrutinib in Patients With High Risk CLL | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jan 24, 2022 | clinicaltrials |
| NCT02589860 | Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant | withdrawn | — | 0 | Sherif S. FaragOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT04918511 | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma(COAST) | withdrawn | Phase 1 | 0 | Oncopeptides ABINDUSTRY | 1 | Nov 26, 2021 | clinicaltrials |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT03943342 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | withdrawn | Phase 2 | 0 | Kerry RogersOTHER | 0 | Nov 5, 2021 | clinicaltrials |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | withdrawn | Phase 1 | 0 | Medigene AGINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant(Immuno-POWER) | withdrawn | Phase 2 | 0 | Natalie CallendarOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | withdrawn | Phase 1 / Phase 2 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma(PLACARD) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Aug 17, 2021 | clinicaltrials |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | withdrawn | Phase 3 | 0 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT04621955 | Observational Study of Home Administration of Carfilzomib(KARE-2) | withdrawn | — | 0 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT04293900 | Diet, Physical Activity and Body Composition Changes During R-CHOP(R-CHOP-OS) | withdrawn | — | 0 | George Washington UniversityOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | withdrawn | Phase 1 | 0 | Bellicum PharmaceuticalsINDUSTRY | 0 | Oct 5, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04355039 | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 0 | Aug 19, 2020 | clinicaltrials |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT03506802 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma(NYSCT MM) | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03145870 | Prevalence of Asymptomatic Thrombosis in Multiple Myeloma | withdrawn | N/A | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 17, 2020 | clinicaltrials |
| NCT03983486 | Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma(CIF-PM) | withdrawn | — | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 17, 2020 | clinicaltrials |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03617484 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial(DARALLO) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT03328936 | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation(IDEALL) | withdrawn | Phase 2 | 0 | TakedaINDUSTRY | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT01571726 | Imaging Studies and the Development of Multiple Myeloma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT01660997 | MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT01647165 | Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 12, 2019 | clinicaltrials |
| NCT02682953 | Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03952832 | Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02776891 | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Oct 10, 2019 | clinicaltrials |
| NCT03232307 | Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 22, 2019 | clinicaltrials |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Aug 14, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 29, 2022source: clinicaltrials